Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Vivus Wins US Approval to Sell New Diet Drug Qsymia


Diet pill maker wins nod from FDA to become second company cleared to sell weight-loss treatment this year.

MINYANVILLE ORIGINAL Let the diet pill wars begin. Vivus (VVUS) was approved by US officials to sell its diet drug, Qsymia, setting up a battle for the prescriptions of millions of obese Americans.

Vivus will compete with Arena Pharmaceuticals (ARNA), which is preparing its own launch of a diet drug.

The announcement came after USA Today inadvertently put out a story online Tuesday that reported the drug was approved. The story was pulled and USA Today made a statement about the goof. In that article, Vivus President Peter Tam was quoted as saying he didn't believe insurance companies would initially cover the cost of the drug. Without revealing a price, he told the paper it won't be "outrageous."

Shares of Vivus bounced around all day Tuesday. They closed down 8% to $26.46 but are still up more than 170% this year.

The competition will certainly depend heavily on the marketing message for the drugs' safety and effectiveness. Vivus may claim it has a more effective drug but its product also carries safety risks. The approval comes with an agreement that Vivus conduct a so-called risk evaluation and mitigation strategy to inform women of potential birth defects caused by taking the drug.

One of the ingredients in Qsymia (formerly known as Qnexa) is topiramate, which poses the risk of cleft lips in newborns of women taking the drug, according to the FDA and Vivus' own studies. Topiramate already is on the market to treat epileptic seizures and migraine headaches.

Vivus also must perform post-approval safety studies, including research to assess cardiovascular risk of taking the diet drug.

Last month, the FDA approved Arena's diet pill Belviq for sale in the US, making it the first new weight loss drug approved in this country in more than a decade. (See Arena Pharmaceuticals' Diet Pill Approved for Sale in US.)

Both Vivus and Arena won backing of expert advisers to the FDA earlier this year. The companies and rival Orexigen Therapeutics (OREX) argue that obesity has become an epidemic in this country, contributing to a number of health issues such as diabetes and heart disease.

Vivus is the only company among the three diet pill makers who doesn't have a development partner, a fact that has led to speculation that it may be acquired. Arena is partnered with Japanese drug maker Eisai, while Orexigen is linked up with another company from Japan, Takeda Pharmaceutical (TKPYY). Orexigen is more than two years away from even being considered again for approval but the company believes it can compete. (See Diet Pill Maker Orexigen Sees Room for Three Rivals.)

It hasn't been an easy road for the diet drug companies. The FDA rejected Vivus and Arena's new drug applications in 2010 and Orexigen's in early 2011 because of fear of side effects. Abbott Laboratories (ABT) pulled its diet pill Meridia from the market in 2010 due to concerns about heart attack and stroke risk. The diet pill combination known as fen phen was taken off the US market in 1997 because of risk of heart valve damage.

Vivus, Arena, and Orexigen drugs all carry safety risks. When the FDA approved Belviq, it said obesity is a "major public health concern," and said the benefits outweighed the risks of the drugs. Last night, the agency made similar remarks.

Shares of Arena fell 1% Tuesday to $11.04 and Orexigen dropped 4% to $7.14.

Vivus is holding a conference call this morning at 8:30 EDT. Here's the company's press release.

Twitter: @brettchase

Follow the markets all day every day with a FREE 14 day trial to Buzz & Banter. Over 30 professional traders share their ideas in real-time. Learn more.
< Previous
  • 1
Next >
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
Featured Videos